Results 1 to 10 of about 32,821 (278)

Design and Production of Bispecific Antibodies [PDF]

Antibodies, 2019
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang, Yiqun Chen, Jaeyoung Park, Xiao Liu, Yifeng Hu, Tiexin Wang, Kevin McFarland, Michael J. Betenbaugh   +7 more
doaj   +4 more sources

Bispecific antibodies in cancer immunotherapy [PDF]

Therapeutic Advances in Vaccines and Immunotherapy, 2018
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and ...
Eva Dahlén, Niina Veitonmäki, Per Norlén   +2 more
doaj   +3 more sources

Bispecific antibodies for viral immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura, Alexandra Y. Soare, Jonathan R. Lai   +2 more
doaj   +4 more sources

A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies [PDF]

Frontiers in Pharmacology
Over the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with the emergence of immune checkpoint-targeting bispecific antibodies.
Yiyang Xu, Siyuan Yang, Qi Rao, Yuan Gao, Guanyue Zhou, Dongmei Zhao, Xinsheng Shi, Yi Chai, Chen Zhao, Chen Zhao   +9 more
doaj   +2 more sources

Bispecific antibody for lung cancer: mechanisms and clinical insights [PDF]

Frontiers in Immunology
Lung cancer is a refractory malignancy. Although various therapeutic options, including targeted therapies, immune checkpoint inhibitors, and systemic chemotherapy, have significantly improved the prognosis of lung cancer patients, five-year survival ...
Wei Chen, Afang Zhou, Yunfeng Zhou
doaj   +2 more sources

Bispecific antibodies in follicular lymphoma

Haematologica
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
doaj   +3 more sources

Bispecific antibody toxicities. [PDF]

CMAJ
Britto J, Mian H, Davies GA, Balitsky AK.   +3 more
europepmc   +3 more sources

Production of native bispecific antibodies in rabbits. [PDF]

PLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +1 more source

Identification of natural bispecific antibodies against cyclic citrullinated peptide and immunoglobulin G in rheumatoid arthritis. [PDF]

PLoS ONE, 2011
BACKGROUND: Previous studies indicate that natural bispecific antibodies can be readily produced in vivo when the body is simultaneously stimulated with 2 distinct antigens.
Wei Wang, Jinming Li
doaj   +1 more source

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

mAbs, 2021
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka, Wolfgang Schaefer, Christian Klein   +2 more
doaj   +1 more source